- Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
- Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
- Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
- Biohaven Announces Proposed Public Offering of Common Shares
- Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
More ▼
Key statistics
On Friday, Biohaven Ltd (BHVN:NYQ) closed at 35.10, 115.34% above the 52 week low of 16.30 set on May 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.26 |
---|---|
High | 37.15 |
Low | 34.60 |
Bid | 34.51 |
Offer | 35.42 |
Previous close | 35.23 |
Average volume | 1.92m |
---|---|
Shares outstanding | 88.29m |
Free float | 72.29m |
P/E (TTM) | -- |
Market cap | 3.10bn USD |
EPS (TTM) | -6.83 USD |
Data delayed at least 15 minutes, as of Jun 01 2024 00:00 BST.
More ▼